Jemma Arakelyan (@jarakelyan28092) 's Twitter Profile
Jemma Arakelyan

@jarakelyan28092

Medical Oncologist, CEO at the Institute of Cancer and Crisis, Ph.D. candidate, Drug Discovery Lab, CityU📍Hong Kong

ID: 1754129115404451840

linkhttps://www.cancerandcrisis.org calendar_today04-02-2024 13:06:09

157 Tweet

210 Followers

576 Following

Jemma Arakelyan (@jarakelyan28092) 's Twitter Profile Photo

🌟 Join Us for the Second Oncothon! 🌟On February 15, International Childhood Cancer Day, we are coming together to raise vital funds for pediatric cancer research. 🎗️@GevorgTamamyan OncoDaily Maria (Masha) Babak, PhD #Oncothon #ChildhoodCancer #PediatricResearch #MakeADifference

OncoDaily (@oncodaily) 's Twitter Profile Photo

🎗️At the Second Global OncoThon by OncoDaily, Jemma Arakelyan (Jemma Arakelyan), Medical Oncologist and CEO at the Institute of Cancer and Crisis (Institute of Cancer and Crisis), shared her heartfelt perspective on the challenges faced by young cancer patients, reflecting on her experiences

🎗️At the Second Global OncoThon by OncoDaily, Jemma Arakelyan (<a href="/JArakelyan28092/">Jemma Arakelyan</a>), Medical Oncologist and CEO at the Institute of Cancer and Crisis (<a href="/cancerandcrisis/">Institute of Cancer and Crisis</a>), shared her heartfelt perspective on the challenges faced by young cancer patients, reflecting on her experiences
The Babak Lab HK (@babaklab) 's Twitter Profile Photo

Thrilled to announce our new publication in Pharmaceutics: "Exploring the Anticancer Potential of NO-Donor Oxadiazole Assemblies Against Malignant Pleural Mesothelioma"! 🎉 We've developed novel NO-donor compounds showing exceptional promise against MPM. These compounds

Thrilled to announce our new publication in Pharmaceutics: "Exploring the Anticancer Potential of NO-Donor Oxadiazole Assemblies Against Malignant Pleural Mesothelioma"! 🎉 We've developed novel NO-donor compounds showing exceptional promise against MPM. These compounds
OncoDaily (@oncodaily) 's Twitter Profile Photo

🎙️A Journey of Hope: Norman Ng’s Inspiring Story In this episode of OncoInfluencers, Jemma Arakelyan interviews Norman Ng, a lung cancer survivor and Director of Patient Advocacy at Healthcare Thinkers. Norman shares his personal journey with stage 4 lung cancer, his work

🎙️A Journey of Hope: Norman Ng’s Inspiring Story

In this episode of OncoInfluencers, <a href="/JArakelyan28092/">Jemma Arakelyan</a> interviews Norman Ng, a lung cancer survivor and Director of Patient Advocacy at Healthcare Thinkers. Norman shares his personal journey with stage 4 lung cancer, his work
Stephen V Liu, MD (@stephenvliu) 's Twitter Profile Photo

Gut microbiota from Phase III JCOG2007 (NIPPON) trial of 1L pembro/chemo vs nivo + ipi/chemo in NSCLC JTO & JTO CRR. Fusicatenibacter & Butyricicoccus associated with longer OS, fewer AEs, more benefit with nivo/ipi. Microbiome impact could be massive. jto.org/article/S1556-…

Jemma Arakelyan (@jarakelyan28092) 's Twitter Profile Photo

This truly feels like a dream come true. I will be attending the Lindau Meeting with #NobelPrize winners!  A huge thank you to my mentor Maria (Masha) Babak, PhD, City University of Hong Kong and #theCroucherFoundation for making this possible!

This truly feels like a dream come true. I will be attending the Lindau Meeting with #NobelPrize winners!   
A huge thank you to my mentor <a href="/babak_phd/">Maria (Masha) Babak, PhD</a>, City University of Hong Kong and  #theCroucherFoundation for making this possible!
Jemma Arakelyan (@jarakelyan28092) 's Twitter Profile Photo

Just visited the HK Herbarium and it was fascinating! 🌿 The variety of plant specimens and the dedication to preserving biodiversity is truly impressive. Highly recommend checking it out! The Babak Lab HK #HKHerbarium #NatureExploration

Just visited the HK Herbarium and it was fascinating! 🌿 The variety of plant specimens and the dedication to preserving biodiversity is truly impressive. Highly recommend checking it out! <a href="/Babaklab/">The Babak Lab HK</a> #HKHerbarium #NatureExploration
Jemma Arakelyan (@jarakelyan28092) 's Twitter Profile Photo

This is my first faculty invitation from ASCO ! Looking forward to learning and contributing my humble presence. The ASCO Post 🌟 #ASCO2025 #Grateful #CancerResearch #GlobalCancerCare #ICC

This is my first faculty invitation from <a href="/ASCO/">ASCO</a> ! Looking forward to learning and contributing my humble presence. <a href="/ASCOPost/">The ASCO Post</a> 🌟 #ASCO2025 #Grateful #CancerResearch #GlobalCancerCare #ICC
OncoDaily (@oncodaily) 's Twitter Profile Photo

Jemma Arakelyan: Insights on the trial of Balstilimab + Botensilimab in Metastatic NSCLC Jemma Arakelyan Immune Oncology Research Institute oncodaily.com/science/jemma-… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedEd #MedNews #Balstilimab #Botensilimab #NSCLC

Jemma Arakelyan: Insights on the trial of Balstilimab + Botensilimab in Metastatic NSCLC
<a href="/JArakelyan28092/">Jemma Arakelyan</a> <a href="/ImmoncInstitute/">Immune Oncology Research Institute</a> 

oncodaily.com/science/jemma-…

#OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedEd #MedNews #Balstilimab #Botensilimab #NSCLC
touchONCOLOGY (@touchoncology) 's Twitter Profile Photo

🌟 #FutureLeader2025 Dr Jemma Arakelyan on how personal loss fuels her mission to drive innovation & compassion in oncology care. 📖 Read her story: touchoncology.com/insight/dr-jem… Jemma Arakelyan #FutureLeaders2025 #OncologyLeadership #PrecisionMedicine #WomenInOncology

🌟 #FutureLeader2025 Dr Jemma Arakelyan on how personal loss fuels her mission to drive innovation &amp; compassion in oncology care.

📖 Read her story: touchoncology.com/insight/dr-jem…

<a href="/JArakelyan28092/">Jemma Arakelyan</a>  #FutureLeaders2025 #OncologyLeadership #PrecisionMedicine #WomenInOncology
soria (@jsoriamd) 's Twitter Profile Photo

🧬 MSI-H = hallmark of mismatch repair (MMR) deficiency. 🧵 Prevalence: ~30% endometrial, ~10% CRC, ~8% gastric. But not all MSI-H/dMMR tumors are alike: 1️⃣ MSH2/MSH6 loss → ↑ TMB, better ICI response 2️⃣ PTEN/AKT1 mutations → ICI resistance Checkpoint blockade is now 1L in CRC

🧬 MSI-H = hallmark of mismatch repair (MMR) deficiency.
🧵 Prevalence: ~30% endometrial, ~10% CRC, ~8% gastric.
But not all MSI-H/dMMR tumors are alike:
1️⃣ MSH2/MSH6 loss → ↑ TMB, better ICI response
2️⃣ PTEN/AKT1 mutations → ICI resistance
Checkpoint blockade is now 1L in CRC
OncoDaily (@oncodaily) 's Twitter Profile Photo

Thanks to my friend Norman Ng, I had the privilege of meeting Dr. Hui Pun, a true visionary in medical oncology - Jemma Arakelyan oncodaily.com/url/296381 #OncoDaily #Oncology #Cancer #Health #Medicine #MedX

Thanks to my friend Norman Ng, I had the privilege of meeting Dr. Hui Pun, a true visionary in medical oncology - <a href="/JArakelyan28092/">Jemma Arakelyan</a> 

oncodaily.com/url/296381

#OncoDaily #Oncology #Cancer #Health #Medicine #MedX
OncoDaily (@oncodaily) 's Twitter Profile Photo

Ready to learn, share, and connect at ASCO 2025 - Jemma Arakelyan ASCO oncodaily.com/blog/asco-2 #ASCO2025 #Cancer #InstituteOfCancerAndCrisis #OncoDaily #Oncology #MedEd #MedX

Ready to learn, share, and connect at ASCO 2025 - <a href="/JArakelyan28092/">Jemma Arakelyan</a> 
<a href="/ASCO/">ASCO</a> 

oncodaily.com/blog/asco-2

#ASCO2025 #Cancer #InstituteOfCancerAndCrisis #OncoDaily #Oncology #MedEd #MedX